Biogen’s Alzheimer’s Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

🌐 Barron's —
Biogen’s Alzheimer’s Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

AI Summary

Despite Biogen's Alzheimer’s drug falling short of initial therapeutic targets, the company's stock has seen unexpected growth. This raises questions about market sentiment and investor response in the pharmaceutical sector amidst setbacks in drug efficacy.

Markets Health Biogen Alzheimer’s drug stock market pharmaceuticals investment

Read original source →